Valvular Heart Disease News and Research

RSS

St. Jude Medical initiates Portico Transfemoral European Trial in severe aortic stenosis

St. Jude Medical, Inc., a global medical device company, today announced the first patient implant of its 25 mm Portico Transcatheter Aortic Heart Valve using the Transfemoral Delivery System in its ongoing European trial.

5 Feb 2013

SLU researchers to test new screening method for MPS disorders among infants

Researchers at Saint Louis University have received a five-year, $2.5 million National Institutes of Health grant to test a new method of screening newborns for a group of rare, but serious genetic disorders that affect approximately 200 babies born in the U.S., each year.

11 Jan 2013

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA’s review to be completed in the first half of 2013.

7 Jan 2013

Most women with heart disease can shun advice to avoid pregnancy

The majority of women with structural or ischemic heart disease can safely undergo pregnancy with extensive pre-evaluation and high-quality care, say researchers.

18 Sep 2012

Patients with severe aortic stenosis can profit from TAVI procedure

Transcatheter aortic valve implantation (TAVI) leads to meaningful improvements in health-related quality of life in patients with severe aortic stenosis that are maintained for at least 1 year, according to a study presented at ESC Congress 2012.

28 Aug 2012

Study explores gender-related differences in patients hospitalized for acute heart failure

Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings were presented by Dr John T. Parissis from Greece.

27 Aug 2012

Arena receives FDA approval for Belviq to treat obesity

The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for chronic weight management.

28 Jun 2012

Patients with mitral regurgitation live longer after surgery

Patients with mitral regurgitation, a type of valvular heart disease common in the elderly, are living longer after surgery, Yale School of Medicine researchers report in the journal Circulation: Cardiovascular Quality and Outcomes.

11 May 2012

Transcatheter Valve Therapies event to take place from June 2-5

Press registration is now open for Transcatheter Valve Therapies: An Advanced Scientific and Clinical Workshop (with LAA Occlusion) at http://www.tvtconference.com/conference/press-registration.html. TVT is a unique educational event, offering an in-depth review of the diagnostic and therapeutic options for the treatment of valvular heart disease.

4 May 2012

Four leading organizations release recommendations to ensure optimal care of TAVR patients

Four leading heart organizations representing cardiologists and cardiothoracic surgeons released initial recommendations today for creating and maintaining transcatheter aortic valve replacement (TAVR) programs.

2 Mar 2012

Leading medical groups collaborate to ensure consistent, responsible uptake of TAVR

With the U.S. Food and Drug Administration's recent approval of transcatheter aortic valve replacement (TAVR) for patients with aortic valvular stenosis, the American College of Cardiology Foundation (ACCF), along with the American Association for Thoracic Surgery (AATS), the Society for Cardiovascular Angiography and Interventions (SCAI) and the Society of Thoracic Surgeons (STS), today released an expert consensus document to provide important guidance on its use.

1 Feb 2012

Gilenya prevents and reverses symptoms of ventricular hypertrophy

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

30 Jan 2012

Imaging is about finding the most appropriate way to assess heart disease

"The idea is that we're using the most appropriate technology to address individual clinical questions rather than just focusing on one technique," explains EAE President Dr Luigi Badano, from the University of Padua, Italy.

23 Nov 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.

From Medtronic 5 Nov 2011

EAE, ASE to issue echocardiography guidelines for early detection of cardio toxicity

"Considering that the early detection of cardio toxicity is a critical issue for patients undergoing chemotherapy, the ASE and the EAE have come together to write guidelines which will highlight the technical advantages of echocardiography in identifying cardio toxicity early," explained Prof Juan Carlos Plana, Co-Director of the Cardio-oncology Center, Cleveland Clinic, from the ASE. "

21 Oct 2011

ESC to deliver educational programme on cardiovascular disease in Beijing

At over 40%, the mortality rate due to cardiovascular disease (CVD) in China is amongst the highest in the world- and has been rightly described as an epidemic. Its population faces a catalogue of CVD risk factor statistics that expose high levels of obesity, diabetes, cholesterol and blood pressure, and a smoking habit within males that is proving stubborn to address.

13 Oct 2011

Stony Brook University opens new center to treat valvular heart disease

Stony Brook University Medical Center has opened a new Valve Center that offers comprehensive treatment of valvular heart disease.

27 Sep 2011

New guidelines on management of cardiovascular disease in pregnancy

New ESC guidelines emphasise the importance of screening and risk assessment. Pre-existing heart disease is rarely a contraindication to pregnancy - indeed, many women with heart disorders tolerate pregnancy well - but it remains a "major concern" that complications are frequent and in some cases may be life-threatening for both the mother and her child. In Europe maternal heart disease has now become the major cause of maternal death during pregnancy.

26 Aug 2011

Transcatheter valve replacement safe and effective alternative to open-heart surgery

An innovative approach for implanting a new aortic heart valve without open-heart surgery is being offered at Rush University Medical Center to patients with severe aortic stenosis who are at high-risk or not suitable candidates for open heart valve replacement surgery.

27 Jun 2011

Mutations in gene linked to structure of the heart seen in Ebstein's anomaly patients

Ebstein's anomaly is a rare congenital valvular heart disease. Now, in patients with this disease, researchers of the Academic Medical Center Amsterdam in the Netherlands, the University of Newcastle, UK and the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have identified mutations in a gene which plays an important role in the structure of the heart.

16 Feb 2011